Editorials


Treatment of Pulmonary Arterial Hypertension: Great Expectations! G. Subramanian, S. Mehta 403


Review

Botulinum Toxin for Shoulder Pain: A Cochrane Systematic Review J.A. Singh, P.M. Fitzgerald 409

Articles

CD101 Expression and Function in Normal and RA-affected Human T Cells and Monocytes/Macrophages D.V. Jovanovic, L. Boumsell, A. Bensussan, X. Chevalier, A. Mancini, J.A. Di Battista 419

Disease Activity, Smoking, and Reproductive-related Predictors of Poor Prognosis in Patients with Very Early Inflammatory Polyarthritis S.M.M. Verstappen, M.J. McCoy, C. Roberts, N.E. Dale, A.B. Hassell, D.P.M. Symmons; and the Steroids In Very Early Arthritis Investigators 429

Low BMI Is Adversely Associated with Radiographic Joint Damage in Indian Patients with Early RA U.D. Velpula, S. Agrawal, J. Thomas, V.N. Naga Prabu, L. Rajasekhar, G. Narsimulu 434

Direct Cost-Modeling of RA According to Disease Activity Categories in France A. Beresiak, L. Gossec, P. Goupille, et al. 439

The Functional Polymorphism 844 A>G in FcRI (CD89) Does Not Contribute to SSc or RA Susceptibility J.C.A. Broen, M.J.H. Coenen, B. Rueda, et al. 446

IgM Anti-ß2 Glycoprotein I Is Protective Against Lupus Nephritis and Renal Damage in SLE T. Mehrani, M. Petri 450

Identify Biomarkers of Neuropsychiatric SLE by MALDI-TOF-MS Combined with Weak Cation Magnetic Beads L. Sun, H. Chen, C. Hu, et al. 454


Use of Muscle Biopsies for Diagnosis of Systemic Vasculitides B. Hervier, C. Durant, A. Masseau, T. Ponge, M. Hamidou, J-M. Mussini 470

WG Strictly and Persistently Localized to One Organ Is Rare: Assessment of 16 Patients from the French Vasculitis Study Group Database C. Pagnoux, M. Stubb, F. Liferman, et al; for the French Vasculitis Study Group 475

Work Disability in Patients with AS in Norway G. Bakland, J.T. Gran, A. Becker-Merok, B.Y. Nordvåg, J.C. Nossegd 479

Radiographic Bone Damage in Chronic Gout Is Negatively Associated with the Inflammatory Cytokines Soluble IL-6 Receptor and OPG J.-Y. Choe, G.H. Lee, S-K. Kim 485

Valproic Acid Suppresses IL-1ß-induced mPGES-1 Expression in Chondrocytes Through Upregulation of NAB1 N. Zayed, F.E. El Mansouri, N. Chabane, et al. 492

Effect of Sociodemographic Factors on Surgical Consultations and Hip or Knee Replacements Among Patients with OA in British Columbia, Canada M.M. Rahman, J.A. Kopec, E.C. Sayre, et al. 503

Pediatric Rheumatology

TMJ Involvement in Children with JIA E. Cannizzaro, S. Schroeder, L.M. Müller, C.J. Kellenberger, R.K. Saurenmann 510

Anti-IL-1 Treatment for Patients with FMF Resistant to Colchicine S. Özen, Y. Bilginer, N. Aktay Ayaz, M. Calguneri 516

Images in Rheumatology

Unusual Subcutaneous Swellings on the Hand as Primary Presenting Feature of Sarcoidosis S. Moscatelli, S. Simonetti, E. Bartoloni Bocci, R. Gerli 519

Free online via JRheum Full Release option
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Prologue: 2009 Group for Research and Assessment of Psoriasis and PsA (GRAPPA)
P.J. Mease, D.D. Gladman .............................................. 522

GRAPPA Trainees Symposium 2009: A Report from the GRAPPA 2009 Annual Meeting
L.C. Coates, C.T. Ritchlin .............................................. 526

Summary of the International Federation of Psoriasis Associations (IFPA) Meeting: A Report from the GRAPPA 2009 Annual Meeting
L.C. Coates, C.L. Jonckheere, S. Molin, P.J. Mease, C.T. Ritchlin .................. 530

Composite Measures in PsA: A Report from the GRAPPA 2009 Annual Meeting
P.S. Helliwell, O. Fitzgerald, C.V. Strand, P.J. Mease ... 540

Toronto PsA Screening (ToPAS) Questionnaire: A Report from the GRAPPA 2009 Annual Meeting
V. Chandran, D.D. Gladman ........................................... 546

PsA Screening and Evaluation (PASE) Questionnaire and the Role of Dermatologists: A Report from the GRAPPA 2009 Annual Meeting
P. Dominguez, M.E. Husni, A. Garg, A.A. Qureshi .............. 548

Psoriasis Epidemiology Screening Tool (PEST): A Report from the GRAPPA 2009 Annual Meeting
P.S. Helliwell ................................................................. 551

Summary of Minutes of the GRAPPA Meeting Adjacent to the American Academy of Dermatology 67th Annual Meeting

Inflammatory MSK Disease: Identification and Assessment
P.J. Mease ................................................................. 557

Psoriasis and PsA Video Project 2010: A Report from the GRAPPA Annual Meeting
K. Callis Duffin, P.J. Mease ............................................. 562

Current Challenges in the Genetics of PsA: A Report from the GRAPPA 2009 Annual Meeting
P. Rahman ................................................................. 564

Cardiovascular Comorbidities in Psoriasis and PsA: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting
W-H. Boehncke, D.D. Gladman, V. Chandran .................. 567

Correspondence

Safety Advantages of Topical versus Oral NSAID
R.D. Altman ................................................................. 572

Reply U. Makris, M. Kohler, L. Fraenkel ......................... 573

Dermatomyositis in Patients with RA During Adalimumab Therapy T. Nagashima, S. Minota .................................. 574

Reply A.M.G. Brunasso, C. Massone ......................... 574

Letters

Observational Data to Study Medication Outcomes in SSc
M. Hudson, M. Baron, R. Steele ................................... 575

Hypersensitive Joint Reaction After Etanercept Treatment in a Patient with JRA
M.M-H. Guo, K.D. Yang, H-R. Yu, H-C. Kuo ................... 577

Vasculitis, Vitiligo, Thyroiditis, and Altered Hormone Levels After Anti-TNF Therapy
R.G. Lahita, M.A. Vernace ........................................... 579

Acquired Erythrocytosis Upon Treatment with Infliximab for AS M. Antonelli, M. Bupathi, M. Janakiram, P. Hergenroeder, M.A. Khan .......... 581

A Case of MPA with Giant Coronary Aneurysm
H. Kobayashi, I. Yokoe, S. Murata, Y. Kobayashi ........ 583

Correction

Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology

Meetings in Rheumatology ................................................. xiv